Updated survival and ctDNA findings support adjuvant cemiplimab in high-risk CSCC

Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer

ESMO 2026: Highlights and analysis

Lifileucel plus pembrolizumab shows durable responses in first-line advanced melanoma

Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types